{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T09:56:29Z","timestamp":1773050189965,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) show efficacy in the treatment of non-Hodgkin lymphomas (NHL). However, these agents are associated with a unique group of side effects called immune-related adverse events (irAEs). We conducted an observational retrospective\/prospective study on patients with relapsed\/refractory NHL treated with ICI to determine the incidence of irAEs assessing the type, severity, and timing of onset, outcome and relationship with study drugs of these events. Thirty-two patients underwent ICI as single agent (N\u2009=\u200920) or in combination (N\u2009=\u200912). Ten patients (31.3%) developed at least one irAE for a total of 17 irAEs. Median time to presentation of irAEs was 69\u00a0days (range 0\u2013407) with a median resolution time of 16\u00a0days (range 0\u201398). Progression free survival at 24\u00a0months for patients who developed an irAE was 40% and 31.8% for who did not. Overall survival for the two groups did not differ (at 24\u00a0months 40.0% and 62.5% for patients without and with irAE, respectively), but the median for who developed an irAE was not reached. The incidence of irAEs was associated with better long-term survival in NHL treated with ICIs but patients\u2019 disease conditions need to be carefully evaluated to decide the optimal management.<\/jats:p>","DOI":"10.1038\/s41598-022-05861-0","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T11:06:03Z","timestamp":1643799963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4225-4626","authenticated-orcid":false,"given":"Lisa","family":"Argnani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Pelusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Lo Preiato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uberto","family":"Pagotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bertoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"5861_CR1","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1200\/JCO.19.01389","volume":"37","author":"P Armand","year":"2019","unstructured":"Armand, P. et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J. Clin. Oncol. 37, 3291\u20133299 (2019).","journal-title":"J. Clin. Oncol."},{"key":"5861_CR2","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","volume":"129","author":"SJ Kim","year":"2017","unstructured":"Kim, S. J. et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase. Blood 129, 2437\u20132442 (2017).","journal-title":"Blood"},{"key":"5861_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1200\/JCO.18.00766","volume":"37","author":"SM Ansell","year":"2019","unstructured":"Ansell, S. M. et al. Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: A single-arm, phase II study. J. Clin. Oncol. 37, 481\u2013489 (2019).","journal-title":"J. Clin. Oncol."},{"key":"5861_CR4","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","volume":"6","author":"A Younes","year":"2019","unstructured":"Younes, A. et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: A phase 1\/2a study. Lancet Haematol. 6, e67\u2013e78 (2019).","journal-title":"Lancet Haematol."},{"key":"5861_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","volume":"1","author":"X Li","year":"2018","unstructured":"Li, X. et al. Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma. J. Hematol. Oncol. 1, 15 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"5861_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/JCO.19.01056","volume":"38","author":"MS Khodadoust","year":"2020","unstructured":"Khodadoust, M. S. et al. Pembrolizumab in relapsed and refractory mycosis fungoides and s\u00e9zary syndrome: A multicenter phase II study. J. Clin. Oncol. 38, 20\u201328 (2020).","journal-title":"J. Clin. Oncol."},{"key":"5861_CR7","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer, J. R. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 36, 1714\u20131768 (2018).","journal-title":"J. Clin. Oncol."},{"key":"5861_CR8","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","volume":"6","author":"N Delanoy","year":"2019","unstructured":"Delanoy, N. et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: A descriptive observational study. Lancet Haematol. 6, e48\u2013e57 (2019).","journal-title":"Lancet Haematol."},{"key":"5861_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563\u2013580 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"5861_CR10","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","volume":"129","author":"L Nayak","year":"2017","unstructured":"Nayak, L. et al. PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma. Blood 129, 3071\u20133073 (2017).","journal-title":"Blood"},{"key":"5861_CR11","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das, S. & Johnson, D. B. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J. Immunother. Cancer 7, 306 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"5861_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson, B. D. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25, 579 (2007).","journal-title":"J. Clin. Oncol."},{"key":"5861_CR13","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"5861_CR14","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","volume":"34","author":"LE Schnipper","year":"2016","unstructured":"Schnipper, L. E. et al. Updating the American Society of Clinical Oncology value framework: Revisions and reflections in response to comments received. J. Clin. Oncol. 34, 2925\u20132934 (2016).","journal-title":"J. Clin. Oncol."},{"key":"5861_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1200\/JCO.2017.75.8193","volume":"36","author":"LA Levit","year":"2018","unstructured":"Levit, L. A. et al. Streamlining adverse events reporting in oncology: An American Society of Clinical Oncology research statement. J. Clin. Oncol. 36, 617\u2013623 (2018).","journal-title":"J. Clin. Oncol."},{"key":"5861_CR16","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1200\/JCO.2013.49.3981","volume":"31","author":"J P\u00e9ron","year":"2013","unstructured":"P\u00e9ron, J., Maillet, D., Gan, H. K., Chen, E. X. & You, B. Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: A systematic review. J. Clin. Oncol. 31, 3957\u20133963 (2013).","journal-title":"J. Clin. Oncol."},{"key":"5861_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1200\/JCO.2013.52.2219","volume":"32","author":"S Sivendran","year":"2014","unstructured":"Sivendran, S. et al. Adverse event reporting in cancer clinical trial publications. J. Clin. Oncol. 32, 83\u201389 (2014).","journal-title":"J. Clin. Oncol."},{"key":"5861_CR18","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"5861_CR19","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang, D. Y. et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol. 4, 1721\u20131728 (2018).","journal-title":"JAMA Oncol."},{"key":"5861_CR20","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","volume":"30","author":"JC Yang","year":"2007","unstructured":"Yang, J. C. et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 30, 825\u2013830 (2007).","journal-title":"J. Immunother."},{"key":"5861_CR21","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","volume":"13","author":"SG Downey","year":"2007","unstructured":"Downey, S. G. et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res. 13, 6681\u20136688 (2007).","journal-title":"Clin. Cancer Res."},{"key":"5861_CR22","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller, M. et al. Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes. Clin. Cancer Res. 22, 886\u2013894 (2016).","journal-title":"Clin. Cancer Res."},{"key":"5861_CR23","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","volume":"12","author":"S Teraoka","year":"2017","unstructured":"Teraoka, S. et al. Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: A prospective cohort study. J. Thorac. Oncol. 12, 1798\u20131805 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"5861_CR24","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L. L. & Hansen, A. R. Tumour-and class-specific patterns of immune-related adverse events of immunecheckpoint inhibitors: A systematic review. Ann. Oncol. 28, 2377\u20132385 (2017).","journal-title":"Ann. Oncol."},{"key":"5861_CR25","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","volume":"13","author":"K Suresh","year":"2018","unstructured":"Suresh, K. et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: Incidence and risk factors. J. Thorac. Oncol. 13, 1930\u20131939 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"5861_CR26","doi-asserted-by":"publisher","first-page":"05","DOI":"10.2217\/mmt-2017-0028","volume":"5","author":"AC So","year":"2018","unstructured":"So, A. C. & Board, R. E. Real-world experience with pembrolizumab toxicities in advanced melanoma patients: A single-center experience in the UK. Melanoma Manage. 5, 05 (2018).","journal-title":"Melanoma Manage."},{"key":"5861_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.lungcan.2018.09.015","volume":"125","author":"JY Cho","year":"2018","unstructured":"Cho, J. Y. et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. Lung Cancer 125, 150\u2013156 (2018).","journal-title":"Lung Cancer"},{"key":"5861_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.lungcan.2017.11.008","volume":"115","author":"KG Tournoy","year":"2018","unstructured":"Tournoy, K. G. et al. Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals. Lung Cancer 115, 49\u201355 (2018).","journal-title":"Lung Cancer"},{"key":"5861_CR29","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","volume":"26","author":"TW Chen","year":"2015","unstructured":"Chen, T. W., Razak, A. R., Bedard, P. L., Siu, L. L. & Hansen, A. R. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann. Oncol. 26, 1824\u20131829 (2015).","journal-title":"Ann. Oncol."},{"key":"5861_CR30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","volume":"18","author":"JA Thompson","year":"2020","unstructured":"Thompson, J. A. et al. NCCN Guidelines insights: Management of immunotherapy-related toxicities, version 1. 2020. J. Natl. Compr. Can. Netw. 18, 230\u2013241 (2020).","journal-title":"J. Natl. Compr. Can. Netw."},{"key":"5861_CR31","doi-asserted-by":"publisher","first-page":"e1911519","DOI":"10.1001\/jamanetworkopen.2019.11519","volume":"2","author":"D Hsiehchen","year":"2019","unstructured":"Hsiehchen, D., Watters, M. K., Lu, R., Xie, Y. & Gerber, D. E. Variation in the assessment of immune-related adverse event occurrence, grade, and timing in patients receiving immune checkpoint inhibitors. JAMA Netw. Open 2, e1911519 (2019).","journal-title":"JAMA Netw. Open"},{"key":"5861_CR32","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1053\/j.seminoncol.2019.10.003","volume":"46","author":"A Cortellini","year":"2019","unstructured":"Cortellini, A., Buti, S., Agostinelli, V. & Bersanelli, M. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. Semin. Oncol. 46, 362\u2013371 (2019).","journal-title":"Semin. Oncol."},{"key":"5861_CR33","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","volume":"7","author":"Y Zhai","year":"2019","unstructured":"Zhai, Y. et al. Endocrine toxicity of immune checkpoint inhibitors: A real-world study leveraging US Food and Drug Administration adverse events reporting system. J. Immunother. Cancer 7, 286 (2019).","journal-title":"J. Immunother. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05861-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05861-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05861-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T21:40:36Z","timestamp":1669326036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05861-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["5861"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-05861-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"assertion":[{"value":"27 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1753"}}